Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more
Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the...
New U.S. patent issued for ZTALMY® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September 2042 Marinus continues to grow its IP portfolio...
Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE Marinus Pharmaceuticals...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...
Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0269 | 8.96367877374 | 0.3001 | 0.46 | 0.2603 | 13068774 | 0.37970975 | CS |
| 4 | -1.403 | -81.098265896 | 1.73 | 1.96 | 0.2603 | 6038212 | 0.43232386 | CS |
| 12 | -0.923 | -73.84 | 1.25 | 1.97 | 0.2603 | 2408991 | 0.60403305 | CS |
| 26 | -1.073 | -76.6428571429 | 1.4 | 1.97 | 0.2603 | 1622001 | 0.84720588 | CS |
| 52 | -6.583 | -95.2677279305 | 6.91 | 11.26 | 0.2603 | 1372477 | 2.14541066 | CS |
| 156 | -11.183 | -97.1589921807 | 11.51 | 13.15 | 0.2603 | 763237 | 4.34232206 | CS |
| 260 | -0.853 | -72.2881355932 | 1.18 | 20.04 | 0.2603 | 1075580 | 4.22925223 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
